In this difficult time with the ongoing COVID-19 outbreak, we hope all of you are healthy and are doing well. Given the unique complexity of COVID-19, it has become increasingly clear that many tools and new innovations are needed in the fight against this pandemic. We have been hard at
Read more
We are having a great start to 2019! Here we will highlight our recent big win at the UC Systemwide Pitch Competition and the progress we are making on several R&D projects in our pipeline, particularly in cancer liquid biopsy and further expansion of the detection capability of our IC3D
Read more
Beating out the competition, UCI Applied Innovation startup Velox Biosystems presented their winning pitch at the third annual UC Entrepreneur Pitch Competition in Monterey, California. Check out the write up from Applied Innovation to learn more.
Read more
In collaboration with Prof. Weian Zhao’s Lab at UC Irvine, Velox has published an article demonstrating the superior sensitivity of IC3D in liquid biopsy applications. In the publication, “An Ultrasensitive Test for Profiling Circulating Tumor DNA using Integrated Comprehensive Droplet Digital Detection” (Lab Chip, 2019), we demonstrated that the IC3D system
Read more
After we highlighted our Point-of-care UTI Screening and Antibiotic Resistance Test project in the last Velox newsletter, a top global diagnostics company contacted us unexpectedly. They acknowledged that UTI represents a very significant, but somewhat neglected market opportunity, and that they have been looking for solutions for the point-of-care setting. Learn more about Velox's
Read more
We have made HUGE progress on the Urinary Tract Infection (UTI) project: Rapid, Point-of-Care, UTI Screening and Antibiotic Susceptibility Testing. We will have more announcement in the upcoming Velox Q2/Q3 Newsletter. In the meanwhile, please check out this cool Velox UTI Video.
Read more
Right off the bat, we will tell you that this Velox newsletter is different from the previous ones. We will be talking about UTI (Urinary Tract Infection) and a huge clinical milestone that Velox has completed: a blinded clinical feasibility study with 26 patient samples for a rapid UTI diagnostic product. So why
Read more
Wow, it seems to be just in the blink of an eye that the year end and the holiday season have almost jumped upon us! A lot has happened in the past six months, so let’s take a quick inventory here of the many accomplishments of our team. Check out the latest news
Read more
Velox is invited to present at the SoCalBio 19th Annual Conference at Hilton Long Beach, Long Beach, CA on September 29, 2017. The annual SoCalBio Investor & Partnering Conference has become the premiere showcase for emerging life-science companies and technologies in Southern California. Our CEO, Dr. Byron Shen, will be speaking
Read more
Velox has been making some exciting strides in recent months.  Check out the latest news and developments in the 2017 Q2 Velox Quarterly Newsletter.  To keep up to date on the latest from Velox, please subscribe to our mailing list using the widget at the bottom of this page.
Read more
CEO and Co-Founder, Dr. Chris Heylman, attended the “I Am A UC Entrepreneur Award Luncheon” on May 5, 2017, in Oakland, CA, hosted by UC President Janet Napolitano and Christine Gulbranson, UC’s Senior Vice President of Innovation and Entrepreneurship.  Dr. Heylman was one of the nineteen winners chosen from more
Read more
Velox was a featured company at this year's LA BioMed Innovation Showcase.  Held March 9th at the Manhattan Beach Marriott, this annual event features the best and brightest medical device and therapeutic startups in Southern California.
Read more